Arsenic trioxide, As 2 O 3 , already used in human anti-cancer therapy, is also an efficient agent against the autoimmune and inflammatory diseases developed in MRL/lpr mice. Inflammatory bowel diseases (IBDs), notably Crohn's disease, which remain without efficient treatment, display autoimmune and inflammatory components. We, therefore, hypothesized that As 2 O 3 may be active on IBDs. Using the 2,4,6-trinitrobenzene sulfonic acid-induced murine model of colitis, we demonstrate that As 2 O 3 used either in a preventive or a curative mode markedly reduced the induced colitis as assessed by macroscopic and microscopic scores, leading to prolonged mice survival. In addition, As 2 O 3 was able to inhibit NF-kB expression and DNA-binding in colon extracts leading to decreased cytokine gene expression (i.e. tumor necrosis factor-a, interleukin(IL)-1b, IL-12, IL-17, IL-18, and IL-23). Interestingly, As 2 O 3 also reduced keratinocyte-derived chemokine (KC), inducible nitric oxide synthase (iNOS) mRNA levels, and myeloperoxidase (MPO) protein expression suggesting an impairment of neutrophils. This was associated with a marked increase of procaspase-3 and induced caspase-3 activation. This caspase-3 co-localized with MPO in the remaining neutrophils suggesting that As 2 O 3 might have eliminated inflamed cells probably by inducing their apoptosis. These results assessed the potent anti-inflammatory effect of As 2 O 3 , that targets both NF-kB and caspase-3 pathways, and suggests a therapeutic potential for Crohn's disease and other severe IBDs.
Introduction
Chronic inflammatory bowel diseases (IBDs) such as Crohn's disease are chronic and relapsing inflammatory disorders characterized by abnormalities in cytokine production and an inflammatory process associated with mucosal damage. 1 The exact etiology and pathogenicity mechanisms of IBD remain actively discussed and include genetic, environmental, immune and microbial factors. 2, 3 All these factors drive inflammatory processes that are directly involved in the pathogenesis of IBD. 4 Interestingly, an autoimmune component has been described in IBD pathogenesis. 5 We have previously demonstrated that arsenic trioxide (As 2 O 3 ) is an efficient therapeutic agent for lymphoproliferative and autoimmune disorders in MRL/lpr mice. 6 It is well known that As 2 O 3 has substantial efficiency in the treatment of both newly diagnosed and relapsed human patients with acute promyelocytic leukemia (APL). 7 Furthermore, the discovery of its remarkable efficiency for the treatment of APL has led to the testing of As 2 O 3 for the treatment of other cancers. Around 40 preclinical studies and early clinical testing of As 2 O 3 are on-going in other hematopoietic malignancies and solid tumors. 8 MRL/lpr mice, a well-studied model of immune complex disease with severe autoimmune tissue damage, 9 develop a human lupus-like syndrome and, as in autoimmune lymphoproliferative syndrome, a massive lymphoproliferation due to inactivation of Fas-mediated apoptosis. In this context, As 2 O 3 is able to eliminate autoreactive T-lymphocytes and block the progression of autoimmune diseases leading to significantly prolonged survival of MRL/lpr mice. 6 Therefore, we extended the study of the effects of As 2 O 3 to the new context of IBDs using the 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced murine model of colitis in Balb/c mice. This hapten reagent TNBS-induced colitis has been well characterized 10 among several other animal models of intestinal inflammation. 11 In this model, as well as in the colonic tissue from patients, increased mucosal pro-inflammatory cytokines have been shown to play a key role in sustained inflammatory responses. 12 The expression of these cytokine genes is mainly regulated by the transcription nuclear factor NF-kB, 13 which is the target of numerous therapies used for IBDs.
The TNBS-induced model of colitis resembles human Crohn's disease in terms of its features and profiles of cytokines 14 and genes induced by microarrays. 15 Moreover, various experimental trials using cytokine antibodies or antisense oligonucleotides against NF-kB have indicated that the TNBS-induced murine model of colitis is useful to test new therapeutic strategies for human cases of Crohn's disease. 16 In the present study, we show that As 2 O 3 treatment in a preventive or a curative mode is able to: (i) dramatically prevent or reduce TNBS-induced symptoms of the disease leading to significantly prolonged survival of Balb/c mice; (ii) reduce TNBS-induced colitis in a dose-dependent manner; (iii) inhibit NF-kB expression and DNA-binding in colon extracts leading to a decreased cytokine gene expression; (iv) reduce keratinocyte derived chemokine (KC) and inducible nitric oxide synthase (iNOS) mRNAs, and the myeloperoxidase protein (MPO) level reflecting neutrophilic inflammation; (v) highly enhance procaspase-3 and activate caspase-3 in colon extracts from mice treated with TNBS. In addition, we show a clear co-localization between caspase-3 and MPO within the remaining neutrophils suggesting that neutrophils were eliminated by apoptosis in response to As 2 O 3 . Our results suggest that As 2 O 3 could be a promising therapeutic agent for Crohn's disease and other severe IBDs.
Materials and methods

Reagents and antibodies
The reagents As 2 O 3 and TNBS were from Sigma (St Louis, MO, USA). Goat polyclonal anti-MPO (C-16), rabbit polyclonal anti-NF-kB p65 (sc-109) and goat polyclonal anti-actin (I-19) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal anti-caspase-3 antibody (clone 31A1067) was from Imgenex Corp. (San Diego, CA, USA).
Mice and treatment
Male Balb/c mice (Centre d'Elevage R. Janvier, France), six weeks of age, were maintained in our licensed animal facilities, and experiments were performed according to the Institutional Animal Research Committee recommendations. Twenty-four hours before intracolic instillation, the animals' diet was controlled with 5% sucrose in water ad libitum. Then, under light anesthesia (xylasine at 20 mg/ml, ketamine 500 at 45 mg/ml, from Sigma-Aldrich, St. Louis, MO, USA), groups of 6 mice were challenged by anal instillation at 4 cm depth, of 50 ml of a mix of either 50% ethanol + 50% LPS-free PBS as a control (referred to figure captions and text as PBS), or of 50% ethanol + 50% TNBS (150 mg/g in LPS-free PBS). 14 For the preventive mode, mice were injected intraperitoneally (i.p.) daily with As 2 O 3 at 2.5 or 5 mg/g body weight 4 d before and following TNBS administration. For the curative mode, As 2 O 3 was injected i.p. daily at 5 mg/g body weight from 18 h following TNBS instillation (i.e. when the disease was noted).
Testing the animals at different time points, the abdomen was opened and the whole colon was observed (expecting to see blood). Its length and thickness were accurately measured, then it was opened longitudinally for evaluation (determination of Ameho scores). 17 First, a portion of 5 mm was cut 4 cm from the anal orifice (corresponding to the left angle of the colon) to perform a semi-quantitative evaluation of the lesions after paraffin inclusion (expressed in Wallace scores). 18 The following portions of the descending colon were used for histology and immunofluorescence, for RT-PCR, for MPO, caspase-3 and NF-kB expression by Western blot, and for NF-kB DNA binding by gel-shift assays.
Evaluation of survival rate of the BALB/c mice following As 2 O 3 treatment during 2 months Arsenic trioxide (5 mg/g body weight) was given daily to mice in the preventive mode, starting from 4 d before TNBS instillation, up to day 60. For the curative mode, As 2 O 3 was given daily from 18 h after TNBS administration up to day 60.
Evaluation of the lesions by macroscopic and histopathological examination
The intensity of colitis was evaluated as previously described. 14 Macroscopic and microscopic lesion evaluations following the different treatments were performed according to Wallace 18 and Ameho 17 criteria.
Cytokine and chemokine evaluation by semi-quantitative RT-PCR analysis
RT-PCR was performed using specific primers for interleukin (IL)-1b, tumor necrosis factor (TNF)-a, IL-12 p35, IL-17, IL-18, IL-23 p19, nitric oxide synthase (iNOS), and the murine ortholog gene for IL8 (i.e. KC), as well as HPRT as control. Results were presented as ratios of cytokine/HPRT levels. Primers chosen for PCR were: IL12 p35 fw TACTAGAGAGACTTCTTCCAC AACAAGAG IL12 p35 rev TCTGGTACATCTTCAAGTCCT CATAGA IL-17 fw GCTCCAGAAGGCCCTCAG IL-17 rev CTTTCCCTCGCATTGACA IL-23 p19 fw AGCGGGACATATGAATCTACT AAGAGA IL 23 p19 rev GTCCTAGTAGGGAGGTGTGA AGTTG HPRT fw GACCGGTCCCGTCATGC HPRT rev TCATAACCTGGTTCATCAT CGC Other primers used are described elsewhere. 14 
Electrophoretic mobility shift assay (EMSA) analysis
The EMSA analysis was performed using the doublestranded oligonucleotide NF-kB motif (consensus sequences underlined: 5 0 -AGTTGAGGGGACTTTCC CAGGC-3 0 ) as described. 19 Control included incubation of nuclear extracts with non-radioactive competitors added to the radiolabeled probe and incubated for 30 min before electrophoresis. The identity of NF-kB in the complexes with oligonucleotides was confirmed by the supershift assay with the anti-NF-kB antibody.
Statistical analysis
Results are presented as mean values AE SD. Levels of significance were calculated using the Mann-Whitney test (an asterisk shows significance between data with a threshold of P < 0.05).
Results
Arsenic trioxide prevented or reduced the progression of TNBS-induced colitis BALB/c mice develop severe colitis following TNBS administration, characterized by bloody diarrhea, severe weight loss, macroscopic and microscopic lesions and ulcers in the colon, associated with a dramatic inflammation, all resulting in high mortality.
To evaluate the potential efficiency of As 2 O 3 , it was first given daily in a preventive mode, starting 4 d before TNBS administration, up to the end of the experiment using 2.5 or 5 mg/g body weight. This drug inhibited the macroscopic ( according to Wallace and Ameho criteria, 18 and corresponding scores are summarized in Table 1 . The colon of 5 mg/g As 2 O 3 -treated animals did not show significant differences compared to the colon of PBS-treated animals ( Table 1) . Together, these results reveal a remarkable effect of As 2 O 3 not only in the preventive mode but, more interestingly, in the curative mode where TNBS-induced gut lesions were more pronounced.
Arsenic trioxide administration inhibited the TNBS-induced cytokine mRNAs expression
To explore the molecular mechanisms involved in As 2 O 3 effects on intestinal inflammation, we studied the profile of some cytokines known to play an important role in experimental colitis, as well as in human IBDs. As expected, the levels of TNF-a, IL-1b, IL-12, IL-17, IL-18 and IL-23 mRNAs were unaffected by As 2 O 3 treatment alone, but were highly increased in the colon of TNBS-treated mice compared to that of control (PBS) mice ( Fig. 3) . Remarkably, the mRNA levels of all these TNBS-induced cytokines were almost normalized in response to As 2 O 3 (Fig. 3 ). Nitric oxide synthase (iNOS) plays an important role in intestinal inflammation and is highly expressed in the TNBS model. 20 The TNBS-induced increase of iNOS mRNA level was also reduced in mice treated with As 2 O 3 (Fig. 3 ). In addition, KC, a gene ortholog for IL-8, is known to promote neutrophil recruitment in TNBS-induced colitis. 21 Accordingly, an increased KC mRNA level was observed in colonic extracts from TNBS-treated mice compared to those from PBS or As 2 O 3 -treated mice (Fig. 3) , which was markedly impaired when As 2 O 3 was administrated in the preventive mode ( Fig. 3 ).
Arsenic trioxide altered MPO and caspase-3 expression in colonic extracts from TNBS-treated mice
Myeloperoxidase (MPO) is recognized as a quantitative marker of the neutrophil content of a tissue. 22 Therefore, we determined whether the decreased severity in response to As 2 O 3 of TNBS-mediated colitis in treated mice was associated with an alteration of MPO expression. Western blot analysis of colonic extracts from PBS-or As 2 O 3 -treated mice did not show detectable MPO, whereas TNBS-treated mice highly expressed MPO (Fig. 4A ). Interestingly, As 2 O 3 drastically decreased or even suppressed TNBS-induced MPO expression ( Fig. 4A ), suggesting that the number of TNBS-induced MPO-expressing cells (i.e. neutrophils) was decreased in response to As 2 O 3 .
Caspase-3 is one of the key executioners of apoptosis. Therefore, the same colonic extracts from treated mice, used for determining MPO expression ( Fig. 4A) , were analyzed using anti-caspase-3 antibody recognizing the whole pro-caspase-3 protein of 32 kDa and the cleaved activated form of 18 kDa (Fig. 4B ). Procaspase-3 was not detected in extracts from control mice treated with PBS alone. Procaspase-3 as well as its cleavage product of 18 kDa were faintly detected both in extracts from TNBS-or As 2 O 3 -treated mice depending on the samples tested ( Fig. 4B ). Administration of As 2 O 3 to TNBS-treated mice led to a marked increase of both procaspase-3 and its active cleavage product in colonic extracts tested ( Fig. 4B ), suggesting that these agents might co-operate to induce procaspase-3 expression and that As 2 O 3 likely induced apoptosis in inflamed colonic cells by activating caspase-3.
Taken together, our results demonstrate that, in response to As 2 O 3 , pro-caspase-3 was induced, caspase-3 was activated and MPO expression, evaluating the neutrophil number, 23 was decreased in the same colonic extracts from TNBS-treated mice. This suggests that neutrophils might have been eliminated by apoptosis. Despite the absence of detectable MPO protein by Western blot in the colon samples from mice treated in a preventive way, we analyzed by immunofluorescence whether some remaining MPO-positive neutrophils might also express caspase-3.
Co-localization between caspase-3 and MPO in neutrophils
We performed a double immunofluorescence experiment for caspase-3 and MPO as well as DAPI staining on the colonic sections from the same treated-mice.
Interestingly, administration of As 2 O 3 to TNBS-treated mice was associated with a very clear co-localization of MPO and caspase-3 appearing as dots in the cytoplasm of the rare remaining MPO-expressing cells identified as neutrophils, whose nuclei appeared fragmented with an apoptotic-like aspect in the colonic sections ( Fig. 5) . Together, the results from Figures 4 and 5 suggest that the major colonic inflammatory infiltrate in TNBS-treated mice might have been eliminated by As 2 O 3 -induced caspase-3-dependent apoptosis.
Arsenic trioxide inhibited TNBS-induced NF-B p65 expression and DNA-binding
An increase in NF-kB p65 expression and activation in the colonic tissue of TNBS-treated animals was previously reported. 24 To study the fate of NF-kB p65 expression in TNBS-induced colitis in response to As 2 O 3 , colonic sections and colonic extracts from the same treated mice were analyzed. Immunofluorescence microscopy analysis indicated that NF-kB p65 staining was very intense in colonic sections from TNBS-treated mice compared to the staining of As 2 O 3 -or PBS-treated mice and was mainly localized in the crypt cells and in the lamina propria (Fig. 6A) . Remarkably, the NF-kB p65 staining markedly decreased when As 2 O 3 was used in the preventive mode on TNBS-treated mice (Fig. 6A ). These results were confirmed by Western blot analysis. Nuclear factor-kB p65 was highly induced in colon extract from TNBStreated mice compared to those from PBS-or As 2 O 3treated mice and As 2 O 3 administration inhibited TNBSinduced NF-kB p65 expression in a dose-dependent manner (Fig. 6B) . The NF-kB can be activated rapidly by a variety of stimuli, including inflammatory cytokines.
NF-kB regulation involves phosphorylation of NF-kB subunits and its binding to target DNA elements, leading to the transcription of genes involved in immune and inflammatory responses. Thus, nuclear colonic extracts, from mice treated in a preventive mode, were analyzed by EMSA with a (g-[ 32 ]P)-dATP labelled NF-kB DNA probe. In extracts from TNBS-treated mice, an NF-kB complex was apparent as a band (Fig. 6C, lines 2, 3, 12 ), which was absent in extracts from control PBS-or As 2 O 3treated mice (Fig. 6C, lines 1, 8-10 ). The specificity of the complex formation was confirmed by a competition experiment in the presence of the unlabeled probe ( Fig.  6C, line 13 ) and by the super shift with anti-NF-kB p65 antibodies (Fig. 6C, line 11 ). The drug decreased and even suppressed TNBS-induced NF-kB DNA binding (Fig.  6C, lines 4-7) . This inhibitory effect was also observed when As 2 O 3 was administrated in the curative mode (Fig. 6D) . Taken together, these results show that As 2 O 3 abrogated TNBS-increased NF-kB expression as tested by immunohistochemistry and Western blot and its binding to DNA as tested by EMSA.
Arsenic trioxide significantly prolonged survival of mice
Macro-and microscopic colon damages induced by TNBS were associated with a rapid animal death. Therefore, we tested the effect of As 2 O 3 for 2 months on the survival of mice developing TNBS-induced colitis.
2,4,6-Trinitrobenzene sulfonic acid-treated animals displayed all the previously described symptoms. 25 A 90% mortality rate occurred at day 5 after TNBS administration (Fig. 7) . In contrast, when As 2 O 3 was injected in a preventive mode, mice seemed quasi-normal, similar to those of PBS-or As 2 O 3 -alone treated mice, and nearly 80% of treated mice were alive up to day 60 ( Fig. 7) .
Conversely, when As 2 O 3 was injected in a curative mode, the mortality, induced the first day after TNBS administration, was reduced in 24 h (in all experiments) but some mice had a disturbed behavior for an additional 24 h or 48 h depending on the animal, i.e. reduced motility and appetite, damaged skin and pelage, before coming back to normal. Remarkably, on established disease, As 2 O 3 significantly prolonged mice survival but more time was needed to promote re-establishment ( Fig. 7 ).
Discussion
We show in this report that As 2 O 3 given in a preventive or curative mode is able to either prevent the onset, or to reverse the progression, of TNBS-induced colitis, saving mice from death. It suppressed or reduced all the macroscopic symptoms, including weight loss and the typical bloody hemorrhagic rectocolitis. The beneficial effects of As 2 O 3 were also observed at the microscopic level, particularly the restoration of the structure of mucosal folds, crypts and epithelium lining and the reduction of deep transmural lesions of the lamina, of pro-inflammatory cytokine induction and of the inflammatory infiltrate notably of MPO-positive neutrophils.
The most widely used of the arsenic-based cancer drugs, 26 As 2 O 3 is a poison that has been used successfully to treat APL 7 and well studied in terms of mechanisms of action and clinical application. A new hope for the treatment of autoimmunity was born with our demonstration that the lymphoproliferative and autoimmune syndrome developing spontaneously in the MRL/lpr mouse, a model of human systemic lupus erythematosus, can be cured with As 2 O 3 by targeting activated T-lymphocytes. 6 Recently, it has been reported that As 2 O 3 also promotes neutrophil apoptosis, 27 leading to the prospect that As 2 O 3 might have broader therapeutic implications. 28 However, until the present study, there was no clinical evidence that As 2 O 3 may resolve pathology, such as a chronic inflammatory syndrome, where neutrophils were highly recruited at the site of inflammation. Our present results demonstrate the efficacy of As 2 O 3 in the extended context of IBDs.
A variety of in vitro studies suggest that several mechanisms may contribute to As 2 O 3 effectiveness in vivo. These mechanisms include the alteration of numerous signal transduction pathways, protein modification and degradation resulting in various cellular effects that include apoptosis induction, growth inhibition, signalling, promotion or inhibition of differentiation and angiogenesis. 8 We show here that the major anti-inflammatory effect of As 2 O 3 in the colon was raised through both inhibition of the NF-kB pathway and activation of caspase-3, leading to normalization of pro-inflammatory cytokine mRNA levels and elimination of colonic inflamed cells.
Previous studies have shown that NF-kB expression and activation is markedly increased in Crohn's disease. 24 2,4,6-Trinitrobenzene sulfonic acid-induced NF-kB expression and activation contributes to abnormal cell proliferation, resistance to apoptosis, increased inflammatory responses and disease progression. In mouse models, NF-kB p65 antisense oligonucleotides efficiently prevent increased NF-kB activation and cytokine production and abrogate clinical and histological signs of inflammation suggesting that inhibition of NF-kB activation may be a promising target for patient treatment. 29 We show in this report that NF-kB p65 was highly expressed and activated in colonic sections from TNBS-treated mice and mainly localized in the crypt and lamina propria cells. Remarkably, As 2 O 3 administration in the preventive or curative mode blocked both TNBS-induced NF-kB p65 expression and NF-kB DNA binding, thus negatively regulating NF-kB-dependent gene expression. In addition, we show here that As 2 O 3 targets the caspase-3 pathway in TNBS-treated mice, showing that TNBS and As 2 O 3 most likely co-operate to increase procaspase-3 expression. Such a co-operative effect has never been previously described and is currently under investigation. Moreover, As 2 O 3 induced a high caspase-3 activation which was concomitant with the decrease of TNBS-induced KC mRNAs and MPO expression in response to As 2 O 3 , suggesting that neutrophils might have been either not recruited or eliminated by apoptosis, possibly in a caspase-3 dependent manner in response to As 2 O 3 .
The effectiveness of As 2 O 3 in human APL patients 7 and in the MRL/lpr mice model 6 (or in the murine TNBS-induced colitis, this paper) have, in common, targeting the cells involved in these different pathologies by inducing their apoptosis. How this mechanism is regulated remains to be studied.
Human IBD treatments remain a matter of debate, even if immunosuppressant combining strategies have provided opportunities to improve and maintain the quality of life for IBDs patients in recent years. 30 However, some patients still remain non-responders or finally relapsed even after anti-TNF-a treatment. Therefore, there is an increased interest in finding alternative treatments with fewer side effects. Several attempts have been made to target specific cytokine activation pathways in human IBDs. 31 More recently, it was reported that intestinal inflammation was associated with IL-23 producing intestinal dendritic cells and IL-17 within the intestine, identifying IL-23 as an effector within the innate immune system. 32 Remarkably, in TNBS-induced colitis, As 2 O 3 normalizes the production of deregulated pro-inflammatory cytokines (TNF-a, IL-1b, IL-12 and IL-18, IL-17, and IL-23) and also targets oxidative stress by reducing iNOS expression. The dramatic reduction of acute TNBS effects by As 2 O 3 are probably mainly due to anti-inflammatory properties of the drug newly described here in colitis. Unlike therapies using antibodies or soluble receptors specific to only one cytokine, As 2 O 3 targets several cytokines with deregulated expression. It has been reported recently that risk of lymphoma is associated with combination of anti-TNF and immunomodulator therapy for the treatment of Crohn's disease. It should be pointed that As 2 O 3 is efficient in IBD (this study) and cancer and its use alone or in association with other combinations should also prevent the risk of non-Hodgkin lymphoma in IBD patients. The fact that As 2 O 3 activated caspase-3, inhibited the NF-kB pathway in colon extracts from TNBS-treated-mice, in association with the normalization of deregulated cytokines, raises the hope of expending the use of As 2 O 3 to treat severe IBDs in patients refractory to immunosuppressor treatments.
